Top Page
Aiml Resources
(AIML)
Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)
Aiml Resources Business Overview & Revenue Model
Aiml Resources Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 167.31K | 600.14K | 487.50K | 65.41K | 0.00 |
| Gross Profit | 162.81K | 294.86K | 466.01K | 65.41K | 0.00 |
| EBITDA | -4.85M | -1.67M | -1.36M | -3.42M | -1.43M |
| Net Income | -4.59M | -3.29M | -1.42M | -3.17M | -2.73M |
Balance Sheet | |||||
| Total Assets | 3.41M | 329.69K | 1.51M | 2.04M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 2.00M | 216.86K | 14.56K | 525.24K | 3.49M |
| Total Debt | 198.19K | 197.72K | 859.98K | 261.34K | 320.29K |
| Total Liabilities | 855.77K | 1.54M | 1.79M | 1.55M | 1.51M |
| Stockholders Equity | 2.60M | -1.17M | -247.46K | 1.08M | 2.31M |
Cash Flow | |||||
| Free Cash Flow | -3.99M | -1.64M | -634.28K | -3.02M | -959.00K |
| Operating Cash Flow | -3.99M | -1.64M | -634.28K | -3.02M | -931.35K |
| Investing Cash Flow | -1.15K | -325.98K | -210.64K | -1.14M | -11.38K |
| Financing Cash Flow | 5.78M | 2.16M | 374.37K | 1.27M | 4.17M |
Aiml Resources Technical Analysis
Aiml Resources Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$14.18M | -3.73 | ― | ― | 16.04% | -455.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$35.52M | -6.18 | ― | ― | -48.53% | -9.66% | |
44 Neutral | C$12.09M | -2.43 | ― | ― | ― | 48.94% | |
42 Neutral | C$8.15M | -1.76 | ― | ― | ― | 81.01% | |
40 Underperform | C$8.89M | -1.08 | -1143.80% | ― | -64.23% | 18.42% | |
33 Underperform | C$7.64M | -4.83 | ― | ― | ― | -67.11% |
Aiml Resources Corporate Events
AI/ML Innovations Inc. has appointed world-renowned cardiologist and research leader Dr. Paul Dorian as Medical Innovation Architect and Head of its Medical Advisory Board, succeeding Peter Kendall as the company advances clinical validation, regulatory engagement, and global deployment of its AI-powered cardiac diagnostic technologies. Dr. Dorian, who has already been advising the company on product strategy and clinical positioning, is expected to play a pivotal role in shaping AIML’s clinical strategy and ensuring its ECG signal-processing platforms meet stringent standards of clinical relevance, safety, and impact, reinforcing the company’s bid to align cutting-edge AI innovation with frontline cardiac care and strengthen its position in regulated clinical markets.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a strategic collaboration with Finnish wearable sensor maker Movesense to create bundled ECG monitoring solutions that tightly integrate Movesense’s single-lead wearable devices with NeuralCloud’s AI-driven cardiac platforms. The partnership is designed to deliver cost-efficient, Holter-style cardiac monitoring and reporting across clinical and wellness markets by combining proven, programmable ECG hardware with AI-based signal enhancement, labeling and customizable report generation, strengthening AIML’s go-to-market position and expanding its ability to offer complete device-plus-software cardiac solutions that can accelerate deployment and broaden market reach.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a strategic collaboration with Finnish wearable sensor maker Movesense to create bundled ECG monitoring solutions that tightly integrate Movesense’s single-lead wearable ECG hardware with NeuralCloud’s AI-driven cardiac platforms. The partnership is designed to deliver cost-efficient, scalable alternatives to traditional Holter monitoring by combining device-plus-AI offerings for automated ECG analysis, visualization and report generation across clinical, wellness and research settings, strengthening AIML’s go-to-market position and expanding its ability to offer complete, device-enabled cardiac solutions that fit modern digital health workflows.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations Inc., has signed a non-binding commercial term sheet with Lakeshore Cardiology to integrate its CardioYield AI visualization platform, powered by the proprietary MaxYield signal-processing engine, into the clinic’s Holter and ambulatory cardiac monitoring workflows. The staged rollout will begin with internal validation and a limited paid trial at Lakeshore Cardiology, with full systems integration and cloud-based deployment planned once the solution is validated and receives necessary regulatory clearance, positioning AIML to embed its AI-driven ECG analysis more deeply into real-world cardiology practice and potentially raise the standard and efficiency of Holter analysis for clinicians and patients.
The most recent analyst rating on (TSE:AIML) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations Inc. has appointed healthcare and MedTech veteran Erik Suokas as Chief Operating Officer to lead day-to-day operations and drive the commercialization of its AI-driven cardiac platform. The move marks a shift from product development to revenue execution and operational scaling, with Suokas tasked with aligning commercial strategy, contract discipline, delivery readiness, and cross-functional teams to convert growing market interest into repeatable revenue and scalable customer delivery. With more than two decades of experience in regulated healthcare and SaaS environments—and a background spanning clinical, legal, and business training—Suokas is expected to strengthen AIML’s operating backbone, support expansion across clinical, wellness, and enterprise health markets, and enhance the company’s industry positioning as it builds out a more robust commercial and delivery infrastructure.
The most recent analyst rating on (TSE:AIML) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations Inc. has ended its consulting agreement with Campfire Properties Inc., resulting in Peter Kendall’s departure as President and Chief Commercial Officer effective December 29, 2025. CEO and Chairman Paul Duffy will assume the additional role of President, consolidating leadership at the top of the organization and signaling a streamlined executive structure as the company continues to advance its AI-driven digital health platforms.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations Inc. is hosting a live shareholder update to review its achievements in 2025 and outline strategic goals for 2026. The company is focused on advancing the commercialization of its AI-powered healthcare technologies and pursuing regulatory approvals, aiming to drive growth and innovation in the digital health sector.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations Inc. has engaged Guerilla Capital, an investor relations firm, to enhance its communications and investor outreach efforts. This engagement, starting immediately for a 12-month term, aims to strengthen AIML’s market presence and investor relations, potentially impacting its operations and industry positioning positively.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations Inc., has signed a commercial term sheet with Culminate H Labs to integrate its MaxYield™ and Insight360™ platforms into the INTRINSICA DNA-guided biofeedback wellness ecosystem. This partnership enhances INTRINSICA’s capabilities by providing advanced ECG processing and genomic integration, positioning NeuralCloud at the forefront of precision medicine and digital health innovation. The collaboration is expected to transform cardiac monitoring and genomic wellness, offering personalized, predictive health interventions.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions Inc., a subsidiary of AI/ML Innovations Inc., has initiated a pilot collaboration with Cornerstone Physiotherapy to integrate its MaxYield™ and Insight360™ technologies into Cornerstone’s elite athlete performance program. This partnership aims to enhance athlete training by using AI-enhanced ECG signals to provide insights into cardiac performance, potentially expanding NeuralCloud’s reach into sports science and human performance markets.
NeuralCloud Solutions Inc., a subsidiary of AI/ML Innovations Inc., has signed a commercial agreement with Equimetrics to integrate its AI-driven ECG signal processing technology into Equimetrics’ equine cardiac monitoring platforms. This collaboration aims to enhance veterinary health and elite equine performance by providing reliable ECG data for better diagnostics and performance optimization, marking a significant expansion of NeuralCloud’s technology into the veterinary and performance health sectors.
AI/ML Innovations Inc.’s subsidiary, Neural Cloud, has initiated a pilot project with The Hospital for Sick Children to evaluate its MaxYield™ platform in pediatric cardiac care. This collaboration aims to enhance early-stage detection of cardiac deterioration in children by applying advanced AI-based ECG signal processing. The project, led by Dr. Cedric Manlhiot, seeks to improve the accuracy and reliability of AI models in predicting cardiac complications, marking a significant step in developing responsible ECG tools for pediatric cardiology.
AI/ML Innovations Inc. has announced the granting of a U.S. patent for its core ECG signal-processing architecture, which enhances its competitive edge as it moves towards commercialization and regulatory approval. This patent solidifies AIML’s intellectual property position, supporting its strategies in cardiology, remote monitoring, telehealth, and clinical research applications, and underscores the company’s commitment to expanding its IP portfolio.
AI/ML Innovations Inc.’s subsidiary, NeuralCloud Solutions, has partnered with Lonacas Consultants to lead the regulatory submission for its CardioYield™ software in Jamaica. This collaboration is a strategic move to expand NeuralCloud’s presence in the Caribbean by providing affordable, high-quality cardiac diagnostics. The initiative aims to address the growing cardiovascular disease burden in Jamaica by introducing a cost-effective, AI-enhanced ECG monitoring solution. The CardioYield™ platform, combined with a wearable chest strap, promises to improve access to cardiac care, particularly in regions with limited diagnostic resources. This regulatory process is crucial for ensuring the technology’s compliance with local standards and its successful deployment across healthcare facilities in Jamaica.